A first-line diagnostic tool for dyspeptic patients
The use of GastroPanel is a first-line diagnostic tool for dyspeptic patients to optimize the use of endoscopies and improve resource allocation in healthcare settings
biohithealthcare.comCrawled Nov 8, 2026
The use of GastroPanel is a first-line diagnostic tool for dyspeptic patients to optimize the use of endoscopies and improve resource allocation in healthcare settings
Biohit’s FAEX Sample System revolutionizes stool sample collection and processing, integrating seamlessly into diagnostic workflows.
Biohit’s FAEX Sample System is a revolutionary stool sample collection and handling solution for seamless integration into diagnostic workflows.
GastroPanel represents a valuable diagnostic tool for private physicians seeking comprehensive information about their patients’ gastric health.
GastroPanel has emerged as a promising tool for screening gastric cancer (1-3), particularly in regions with high incidence rates such as China and Chile.
Biohit HealthCare Srl is part of a Finnish public company specializing in early diagnosis and prevention of gastrointestinal diseases.
Biohit Oyj’s board elected Vesa Silaskivi, OTT, KTL, as chairman at its meeting on June 14, 2023.
Environmental objectives are an important part of Biohit’s strategy. New aspects of more environmentally friendly activities are being sought all the time.
Biohit traces its origins to the 1970s, when Professor Osmo Suovaniemi founded Labsystems and Eflab.
Biohit integrates environmental goals into its strategy, seeking new ways to operate more sustainably.
Biohit Oyj is a globally operating biotechnology company established in 1988. Biohit is headquartered in Helsinki, Finland and has subsidiaries in Italy and UK.
Biohit reports moderate progress in its strategic projects. A study at Homerton University Hospital, published in January 2025, validated the use of **GastroPanel** for patient triage, supporting its clinical application.
Finnish medical device company **Biohit** secures new distribution rights for its gastrointestinal diagnostic tests. The company specializes in developing and distributing tests focused on digestive health applications. This expansion strengthens its market presence in the medical diagnostics sector.
Biohit advances toward a **2026 U.S. market launch** by pursuing **FDA marketing authorization** for an unspecified product. The company reports the approval process remains on track, positioning it for regulatory clearance next year.
BIOHIT introduces the **GastroPanel Quick Test**, a 15-minute diagnostic tool that identifies *Helicobacter pylori* infections and atrophic gastritis (AG), a precancerous condition. The test aids primary care triage by detecting high gastric acid output alongside these disorders, enabling faster intervention for gastrointestinal issues. It supports early discovery and treatment of related conditions.
A chewing gum containing the amino acid cysteine is being developed to lower cancer risks linked to tobacco and alcohol use. Research conducted at the University of Helsinki supports its efficacy, with the product set for market release in 2023. The gum targets oral and esophageal cancers by neutralizing carcinogens from smoking and drinking.